Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9H1A4
UPID:
APC1_HUMAN
Alternative names:
Cyclosome subunit 1; Mitotic checkpoint regulator; Testis-specific gene 24 protein
Alternative UPACC:
Q9H1A4; Q2M3H8; Q9BSE6; Q9H8D0
Background:
Anaphase-promoting complex subunit 1, also known as Cyclosome subunit 1, plays a pivotal role in cell cycle regulation. It is a component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase. This complex is crucial for controlling progression through mitosis and the G1 phase of the cell cycle by mediating ubiquitination and subsequent degradation of target proteins.
Therapeutic significance:
The protein's involvement in Rothmund-Thomson syndrome 1, characterized by sparse hair, juvenile cataracts, and poikiloderma, highlights its potential as a therapeutic target. Understanding the role of Anaphase-promoting complex subunit 1 could open doors to potential therapeutic strategies for this autosomal recessive disorder.